Table 1.
Patient Characteristics.
| All | Actionable Matched Treated |
Actionable Matched Untreated |
Non-actionable | |
|---|---|---|---|---|
| Total, N (%) | 124 (100) | 22 (17.7) | 32 (25.8) | 70 (56.5) |
| Age, years | ||||
| Median | 59 | 56 | 58 | 61 |
| Range | 17-80 | 27-75 | 17-72 | 20-80 |
| Sex, N (%) | ||||
| Female | 65 (52) | 13 (59.1) | 19 (59.4) | 33 (47.1) |
| Male | 59 (48) | 9 (40.1) | 13 (40.6) | 37 (52.9) |
| Race, N (%) | ||||
| White or Caucasian | 111 (89.5) | 21 (95.5) | 30 (93.8) | 59 (84.3) |
| Asian or Asian American | 5 (4.0) | 1 (3.1) | 3 (4.3) | |
| Black or African American | 4 (3.2) | 1 (3.1) | 5 (7.1) | |
| American Indian | 2 (1.6) | 1 (4.5) | 1 (1.4) | |
| Other or missing | 2 (6) | 2 (2.9) | ||
| Primary tumor site, N (%) | ||||
| Intrahepatic | 88 (71) | 21 (95.4) | 27 (84.4) | 40 (57.1) |
| Extrahepatic perihilar | 10 (8) | 1 (3.1) | 9 (12.9) | |
| Extrahepatic distal | 8 (6) | 2 (6.3) | 6 (8.6) | |
| Gallbladder | 13 (10) | 1 (3.1) | 12 (17.1) | |
| Mixed hepatocellular/ cholangiocarcinoma | 5 (4) | 1 (4.5) | 1 (3.1) | 3 (4.3) |
| First-line systemic therapy, N (%) | ||||
| Gemcitabine/platinum +/- agent | 90 (72.6) | 16 (72.7) | 24 (75.0) | 50 (71.4) |
| Gemcitabine/taxane | 4 (3.2) | 3 (9.4) | 1 (1.4) | |
| 5-fluorouracil based regimen | 15 (12.1) | 2 (9.1) | 1 (3.1) | 12 (17.1) |
| Immunotherapy only | 5 (4.0) | 1 (4.5) | 1 (3.1) | 3 (4.3) |
| Other | 4 (3.2) | 3 (13.6) | 1 (1.4) | |
| Unknown or none | 6 (4.8) | 3 (9.4) | 3 (4.3) | |
| NGS Platform, N (%) | ||||
| MI-ONCOSEQ | 92 (74.2) | 14 (63.6) | 27 (84.4) | 51 (81.4) |
| Other | 32 (25.8) | 8 (36.4) | 5 (15.6) | 19 (27.1) |
| Stage at biopsy, N (%) | ||||
| Resectable | 16 (12.9) | 2 (9.1) | 3 (9.4) | 11 (15.7) |
| Locally advanced unresectable | 11 (8.9) | 1 (4.5) | 4 (12.5) | 6 (8.6) |
| Metastatic | 97 (78.2) | 19 (86.4) | 25 (78.1) | 53 (75.7) |
| Biopsy specimen, N (%) | ||||
| Primary | 61 (49) | 13 (59.1) | 20 (62.5) | 29 (41.4) |
| Metastatic | 63 (51) | 9 (40.9) | 12 (37.5) | 41 (58.6) |
| Biopsy in relation to chemotherapy, N (%) | ||||
| Pre-chemotherapy | 41 (33) | 5 (22.7) | 13 (40.6) | 23 (32.9) |
| Post-chemotherapy | 83 (67) | 17 (77.3) | 19 (59.4) | 47 (67.1) |
NGS, next-generation sequencing; MI-ONCOSEQ, Michigan Oncology Sequencing